{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:05:21Z","timestamp":1790737521002,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T16:30:41Z","timestamp":1678984241000},"page":"2664-2670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The burden of invasive meningococcal disease in the Netherlands, 2011\u20132020"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8762-4822","authenticated-orcid":false,"given":"Marit","family":"Middeldorp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Steens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giske","family":"Lagerweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina M.","family":"van Sorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wieke","family":"Freudenburg-de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"A. M. Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2023.03.017_b0005","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.017_b0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"issue":"8","key":"10.1016\/j.vaccine.2023.03.017_b0015","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current Epidemiology and Trends in Meningococcal Disease\u2014United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.017_b0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"8","key":"10.1016\/j.vaccine.2023.03.017_b0025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/civ506","article-title":"Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex","volume":"61","author":"Stoof","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.017_b0030","unstructured":"Pluijmaekers AJM, de Melker HE. The National Immunisation Programme in the Netherlands: Surveillance and developments in 2020-2021; 2021. 10.21945\/RIVM-2021-0055."},{"key":"10.1016\/j.vaccine.2023.03.017_b0035","doi-asserted-by":"crossref","unstructured":"H Htar MTT, Jackson S, Balmer P, Serra LC, Vyse A, Slack M, et al. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC public health 2020 ; 20(1):1-15. 10.1186\/s12889-020-09946-1.","DOI":"10.1186\/s12889-020-09946-1"},{"issue":"16","key":"10.1016\/j.vaccine.2023.03.017_b0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158","article-title":"Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018","volume":"23","author":"Knol","year":"2018","journal-title":"Eurosurveillance"},{"issue":"12","key":"10.1016\/j.vaccine.2023.03.017_b0045","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/cid\/ciab791","article-title":"Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study","volume":"74","author":"Ohm","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.03.017_b0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.vaccine.2020.12.080","article-title":"Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020","volume":"39","author":"Middeldorp","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.017_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-4513-2","article-title":"Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004\u20132016","volume":"19","author":"Brandwagt","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.017_b0060","doi-asserted-by":"crossref","unstructured":"ansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine 2009 ; 27(17):2394-401. 10.1016\/j.vaccine.2009.01.127.","DOI":"10.1016\/j.vaccine.2009.01.127"},{"key":"10.1016\/j.vaccine.2023.03.017_b0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-61779-346-2_2","article-title":"Classification and pathogenesis of meningococcal infections","author":"Brandtzaeg","year":"2012","journal-title":"Neisseria meningitidis"},{"key":"10.1016\/j.vaccine.2023.03.017_b0070","unstructured":"Klous G, van Hout D, Lagerweij G, van Hoek A, Franz E. Staat van infectieziekten in Nederland, 2020. State of Infectious Diseases in the Netherlands, 2020: Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2021."},{"issue":"21","key":"10.1016\/j.vaccine.2023.03.017_b0075","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2023.03.017_b0080","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/cid\/ciz578","article-title":"The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015\u20132018","volume":"70","author":"Loenenbach","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.017_b0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jinf.2017.10.015","article-title":"Clonal replacement and expansion among invasive meningococcal isolates of serogroup W in France","volume":"76","author":"Hong","year":"2018","journal-title":"J Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2023.03.017_b0090","doi-asserted-by":"crossref","first-page":"30175","DOI":"10.2807\/1560-7917.ES.2016.21.12.30175","article-title":"Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016","volume":"21","author":"Campbell","year":"2016","journal-title":"Eurosurveillance"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.017_b0095","doi-asserted-by":"crossref","first-page":"E454","DOI":"10.33321\/cdi.2016.40.50","article-title":"Rise in invasive serogroup W meningococcal disease in Australia 2013\u20132015","volume":"40","author":"Martin","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2023.03.017_b0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ijid.2021.05.086","article-title":"Recent increased incidence of invasive serogroup W meningococcal disease: A retrospective observational study","volume":"108","author":"Hovmand","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2023.03.017_b0105","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1017\/S0950268809002428","article-title":"Morbidity, mortality and spatial distribution of meningococcal disease, 1974\u20132007","volume":"137","author":"Howitz","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"45","key":"10.1016\/j.vaccine.2023.03.017_b0110","doi-asserted-by":"crossref","first-page":"30395","DOI":"10.2807\/1560-7917.ES.2016.21.45.30395","article-title":"An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015","volume":"21","author":"Lucidarme","year":"2016","journal-title":"Eurosurveillance"},{"issue":"10","key":"10.1016\/j.vaccine.2023.03.017_b0115","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3201\/eid2210.151935","article-title":"Increase in meningococcal serogroup W disease, Victoria, Australia, 2013\u20132015","volume":"22","author":"Carville","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.017_b0120","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2023.03.017_b0125","doi-asserted-by":"crossref","first-page":"30176","DOI":"10.2807\/1560-7917.ES.2016.21.12.30176","article-title":"Increased incidence of invasive meningococcal disease of serogroup C\/clonal complex 11, Tuscany, Italy, 2015 to 2016","volume":"21","author":"Stefanelli","year":"2016","journal-title":"Eurosurveillance"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.017_b0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5604\/17331331.1185912","article-title":"Significance of meningococcal hyperinvasive clonal complexes and their influence on vaccines development","volume":"64","author":"Wa\u015bko","year":"2015","journal-title":"Pol J Microbiol"},{"key":"10.1016\/j.vaccine.2023.03.017_b0135","first-page":"e4","article-title":"An outbreak of severe invasive meningococcal disease due to a capsular switched Neisseria meningitidis hypervirulent strain B: cc11","volume":"25(1):111. e1-","author":"Stefanelli","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"26","key":"10.1016\/j.vaccine.2023.03.017_b0140","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.vaccine.2018.02.038","article-title":"Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010\u20132015","volume":"36","author":"Parikh","year":"2018","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2023.03.017_b0145","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1016\/j.vaccine.2019.08.025","article-title":"Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease","volume":"37","author":"Vestjens","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.03.017_b0150","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jinf.2019.12.008","article-title":"Invasive meningococcal disease: Timing and cause of death in England, 2008\u20132015","volume":"80","author":"Beebeejaun","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2023.03.017_b0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fped.2018.00321","article-title":"Invasive meningococcal disease in the vaccine era","volume":"6","author":"Nadel","year":"2018","journal-title":"Front Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.017_b0160","doi-asserted-by":"crossref","first-page":"e0228020","DOI":"10.1371\/journal.pone.0228020","article-title":"Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database","volume":"15","author":"Huang","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.017_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-022-07129-4","article-title":"Risk of sequelae after invasive meningococcal disease","volume":"22","author":"Voss","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.03.017_b0170","unstructured":"Gezondheidsraad. Vaccinatie tegen meningokokken. Den Haag: Gezondheidsraad; 2018. Report No.: 2018\/28."},{"issue":"49","key":"10.1016\/j.vaccine.2023.03.017_b0175","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1016\/j.vaccine.2020.10.008","article-title":"Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands","volume":"38","author":"Freudenburg-de Graaf","year":"2020","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23002645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:43Z","timestamp":1759404283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23002645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":35,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23002645"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The burden of invasive meningococcal disease in the Netherlands, 2011\u20132020","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}